HomeNDC LookupIngredientsKetoconazole › 51672-1298-01
Ketoconazole 20 mg/g Cream — NDC 51672-1298-01 package photo

Ketoconazole 20 mg/g Cream

by Sun Pharmaceutical Industries, Inc. · 1 TUBE in 1 CARTON (51672-1298-1) / 15 g in 1 TUBE
NDC 51672-1298-01
🏷️ FDA NDC (as labeled) 51672-1298-1 billing pads the package segment with a zero
This package
Contains15 g in 1 tube Cost per g$0.3029 NADAC Per package$4.54 / 15 g Pack sizes3 compare ↓
Also priced by: Medicaid pays $0.5819/unit · Part D plans $0.3356/unit — full pricing hub ↓
Rx only Generic On market Non-controlled
🗂️ Data synced Jul 24, 2026 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
📋 All sources & update times →

🆔 Identity & classification

FDA NDC (as labeled) 51672-1298-1
Product NDC 51672-1298
11-digit billing NDC 51672129801
NCPDP billing unit GM — per gram (weight)
RxCUI 203088
UNII R9400W927I
Application # ANDA075638
SPL Set ID 39b85d6a-9133-42e6-b7f8-58f045e9b9f0
Established class (EPC) Azole Antifungal
Mechanism of action Cytochrome P450 3A4 Inhibitors; Cytochrome P450 3A5 Inhibitors; P-Glycoprotein Inhibitors
Chemical class Azoles
DEA schedule Non-controlled
Marketing category ANDA
Marketing status On market
FDA listing status Listed (active directory)
Marketing start 2002-12-18
Route TOPICAL
Dosage form CREAM
Substance KETOCONAZOLE
GPI-14 90154045003710
GPI class Ketoconazole
GCN Seq No 007334
GCN 31850
HICL code 004132
Ingredient (HICL) Ketoconazole
HIC1 code Q
Therapeutic class — broad (HIC1) Ear/Eye/Nose/Rectum/Topical/Vagina/Other
HIC2 code Q5
Therapeutic class — intermediate (HIC2) Agents Acting Principally On The Skin
HIC3 code Q5F
Therapeutic class — specific (HIC3) Topical Antifungals
AHFS code 08:14.08.00
AHFS class Azole Antifungals
FDB label name KETOCONAZOLE 2% CREAM
FDB brand name Ketoconazole
Legend status F — Federal legend — prescription drug or device
TE code (Orange Book) AB · RLD · RS
Why two NDCs? The FDA registers this code as 51672-1298-1 — a 5-4-1 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the package segment → 51672-1298-01. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.

🏷️ RxNorm drug class

This medicine belongs to the Cortisol Synthesis Inhibitor class.

Pharmacologic class Cortisol Synthesis Inhibitor, Azole Antifungal
Drug family (ATC) Anticorticosteroids, Imidazole and triazole derivatives, Imidazole derivatives
How it works Cytochrome P450 2B6 Inhibitors, Cytochrome P450 3A4 Inhibitors, Cytochrome P450 17A1 Inhibitors, P-Glycoprotein Inhibitors
Where does this data come from?
Therapeutic classes from RxNorm RxClass (U.S. National Library of Medicine) — Established Pharmacologic Class (FDA), ATC drug family (WHO) and mechanism of action, matched by this product’s RxCUI.

🏭 Manufacturer & labeler

LabelerSun Pharmaceutical Industries, Inc.
Application holderSUN PHARMA CANADA INC
FDA applicationANDA075638 (ANDA)
Labeler code51672
First marketedDec 2002
Product typeHuman Prescription Drug
Portfolio889 products on file
The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.

🩺 Clinical

Label name KETOCONAZOLE 2% CREAM Ingredient Ketoconazole
📖 What it is MedlinePlus · NLM

Ketoconazole cream is used to treat tinea corporis (ringworm; fungal skin infection that causes a red scaly rash on different parts of the body), tinea cruris (jock itch; fungal infection of the skin in the groin or buttocks), tinea pedis (athlete's foot; fungal infection of the skin on the feet and between the toes), tinea versicolor (fungal infection of the skin that causes brown or light colored spots on the chest, back, arms, legs, or neck), and yeast infections of the skin. Prescription ketoconazole shampoo is used to treat tinea versicolor. Over-the-counter ketoconazole shampoo is used t...

Read the full MedlinePlus article ↗
📗 Our plain-language guide HelloPharmacist
  • Tinea versicolor is a fungal infection caused by a yeast that normally lives on everyone's skin. When it overgrows, it creates light or dark patches — most commonly on the chest, b...
  • What exactly is tinea versicolor, and will this clear it up completely?
  • The key is to never dispense it directly onto your hands — the foam starts melting the moment it hits warm skin. Instead, press the nozzle into the cap of the can or any cool surfa...
  • How do I actually apply this foam without making a mess?
📖 Read our full Ketoconazole guide →
Where does this data come from?
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.

💊 What it looks like

Color white
One label can cover several strengths, so colors may be combined — always confirm a loose pill against the dispensed prescription label or a pharmacist.
Where does this data come from?
Physical description (imprint, shape, color, scoring, coating) from this product’s FDA Structured Product Labeling (SPL), mirrored from DailyMed / openFDA.

🧪 Inactive Ingredients / Excipients

Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.

💡 Tap an ingredient (hover on desktop) to see what it is and why it’s used.

  • UNII REK4960K2U
    Butylated hydroxyanisole is a synthetic preservative that prevents oils and fats in medicines from spoiling or becoming rancid. It keeps the medicine stable and extends its shelf life.
  • UNII 936JST6JCN
    Cetyl alcohol is a waxy, fatty substance derived from plant or animal sources. It acts as an emulsifier and thickener in medicines, helping blend oil and water components and giving products a smooth, creamy texture.
  • UNII 0RE8K4LNJS
    Isopropyl myristate is an oily liquid made from coconut or palm oil. It's used in medicines as an emollient and penetration enhancer to help the medicine absorb through skin or improve spreadability in topical products.
  • UNII CAL22UVI4M
    A synthetic emulsifier derived from sorbitol and fatty acids. It helps mix oil and water-based ingredients together and improves the texture and stability of the medicine.
  • UNII 6OZP39ZG8H
    Polysorbate 80 is a synthetic emulsifier derived from sorbitol and oleic acid. It helps mix oil and water-based ingredients together in medications and improves how the product disperses in the body.
  • UNII 6DC9Q167V3
    Propylene glycol is a clear liquid derived from petroleum or vegetable sources. It acts as a solvent, humectant, and preservative in medicines, helping dissolve active ingredients and maintain product stability.
  • UNII NVZ4I0H58X
    A waxy substance made from sorbitol and stearic acid. It acts as an emulsifier and stabilizer, helping keep oil and water mixed together and preventing separation in the medicine.
  • UNII 2KR89I4H1Y
    Stearyl alcohol is a waxy, fatty substance derived from natural oils or made synthetically. It acts as an emulsifier and thickener in medicines, helping mix ingredients together and give the product the right texture.
  • UNII 059QF0KO0R
    Water is a liquid solvent that dissolves and mixes ingredients together in liquid medicines, syrups, and injections. It helps distribute the active drug evenly throughout the product.

9 inactive ingredients listed in the exact product block matched to this NDC.

Where does this data come from?
Data sourced from official FDA Structured Product Labeling (SPL) via DailyMedingredient classCode="IACT" elements from the exact product block matched by this NDC. Label-section narrative from DailyMed / the openFDA label index is shown separately when available.

Inactive ingredient FAQ

Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.

💲 Pricing

A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.

Price systemPer gPer package
Retail pharmacies payNADAC · weekly $0.303 $4.54 / 15 g
Medicaid paysCMS SDUD · 12 mo $0.5819 $8.73 / 15 g
Medicare drug plans payPart D · Q2 2026 $0.3356 $5.03 / 15 g
NADAC price history (per g) — tap or hover for the price & month
Dec 2021 Jul 2022 Dec 2025 Aug 2026 $0.531 $0.260
▼ Down 36% over the last 24 months.
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.

🔁 Therapeutic equivalents

ProductLabelerPackNADAC/unitTEStatusPrice vs. this
Ketoconazole 20 mg/g 00093-3219-15 Teva 1 tube $0.303 AB Availability likely
ketoconazole 20 mg/g 00168-0099-15 E. 1 tube $0.303 AB Availability likely
Ketoconazole 20 mg/g 16714-0955-01 NORTHSTAR 1 tube $0.303 AB Availability likely
Ketoconazole 20 mg/g 21922-0025-04 Encube 1 tube $0.303 AB Availability likely
Ketoconazole 20 mg/gthis 51672-1298-01 Sun 1 tube $0.303 AB Availability likely
Ketoconazole 20 mg/g 50090-5265-00 A-S 1 tube AB FDA listed
Ketoconazole 20 mg/g 50090-6046-00 A-S 1 tube AB FDA listed
Ketoconazole 20 mg/g 50090-6069-00 A-S 1 tube AB FDA listed
Ketoconazole 20 mg/g 51407-0279-15 Golden 1 tube AB FDA listed
Ketoconazole 20 mg/g 63187-0774-15 Proficient 1 tube AB FDA listed
Ketoconazole 20 mg/g 63629-8819-01 Bryant 1 tube AB FDA listed
Ketoconazole 20 mg/g 63629-8820-01 Bryant 1 tube AB FDA listed
Ketoconazole 20 mg/g 68071-1709-03 NuCare 30 g AB FDA listed
Ketoconazole 20 mg/g 68071-3512-05 NuCare 15 tubes AB FDA listed
Ketoconazole 20 mg/g 68788-8233-03 Preferred 1 tube AB FDA listed
Ketoconazole 20 mg/g 70518-4236-00 REMEDYREPACK 1 tube AB FDA listed
Ketoconazole Cream 20 mg/g 72189-0422-30 Direct_Rx 30 g AB FDA listed
Ketoconazole 20 mg/g 82804-0091-15 Proficient 1 tube AB FDA listed
Ketoconazole 20 mg/g 85766-0135-15 Sportpharm 1 tube AB FDA listed
Ketoconazole 20 mg/g 87063-0066-15 ASCLEMED 1 tube AB FDA listed
About this product: this is a generic version of the medicine. FDA equivalence ratings are shown when available, and other versions are listed above, least expensive first.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.

Availability & generic status

🏛️
2002
On the market since
Dec 2002
📍
2026
Currently FDA-listed
24 years listed
🔓
·
Generic on the market
this product is a generic
This is a generic drug

This product is an FDA-approved generic. Other versions of the same drug are listed under Therapeutic equivalents, least expensive first.

Where does this data come from?
Patents and exclusivity from the FDA Orange Book (small-molecule drugs), refreshed from public FDA data. Generic launch timing is an estimate, not a guarantee.

🗺️ Medicaid utilization & spend

📍 This exact package only: Medicaid data is reported per full 11-digit NDC — labeler, product and pack size — so every number here is for 51672-1298-01, not the drug overall. Other pack sizes report separately.
💊 Pharmacy benefit only: These are Medicaid outpatient pharmacy claims, billed by NDC. They exclude the medical benefit — clinic- or hospital-administered drugs billed under HCPCS J-codes — so drugs used mostly that way (e.g. Avastin, Lucentis, Keytruda) can look low or missing here. That’s expected, not an error.
📅 Q1 2025 – Q4 2025 · 4 quarters of data
ⓘ The newest quarter is usually incomplete when first published; states restate recent quarters in later CMS releases, so the latest figures typically revise upward. State coverage-policy changes can also shift quarter-to-quarter totals.
Prescriptions last 4 qtrs
18.3K
Units reimbursed last 4 qtrs
421.3K
Gross reimbursed last 4 qtrs
$245.2K
Avg / prescription
$13.41
Avg / unit
$0.5819
Latest quarter Q4 2025
3.8KRx
Medicaid pays / g
$0.5819
gross reimbursed
vs
NADAC / g
$0.3029
acquisition cost
=
Spread
+$0.2790
+92% vs cost
What Medicaid paid per g (before rebates; includes the pharmacy’s dispensing fee) compared with NADAC — the average price pharmacies pay to buy the drug. A positive spread means Medicaid reimbursed more than the purchase price, before manufacturer rebates.
Fee-for-service vs managed care
37% FFS 63% MCO
Fee-for-service · 6,717 Rx Managed care · 11,566 Rx
State Medicaid map
Alaska: no data reported AK Maine: 675 units · 48.4 per 100k residents ME Washington: 16,260 units · 208 per 100k residents WA Idaho: 255 units · 13.0 per 100k residents ID Montana: 375 units · 33.1 per 100k residents MT North Dakota: no data reported ND Minnesota: 1,470 units · 25.6 per 100k residents MN Wisconsin: 7,418 units · 126 per 100k residents WI Michigan: 38,235 units · 381 per 100k residents MI New York: 64,035 units · 327 per 100k residents NY Vermont: no data reported VT New Hampshire: 1,665 units · 119 per 100k residents NH Oregon: 4,575 units · 108 per 100k residents OR Nevada: no data reported NV Wyoming: no data reported WY South Dakota: no data reported SD Iowa: 990 units · 30.9 per 100k residents IA Illinois: 9,345 units · 74.5 per 100k residents IL Indiana: 7,245 units · 106 per 100k residents IN Ohio: 15,314 units · 130 per 100k residents OH Pennsylvania: 27,150 units · 209 per 100k residents PA New Jersey: 60,840 units · 655 per 100k residents NJ Massachusetts: 2,656 units · 37.9 per 100k residents MA California: 66,946 units · 172 per 100k residents CA Utah: no data reported UT Colorado: 1,515 units · 25.8 per 100k residents CO Nebraska: no data reported NE Missouri: 4,920 units · 79.4 per 100k residents MO Kentucky: 4,249 units · 93.9 per 100k residents KY West Virginia: 2,535 units · 143 per 100k residents WV Virginia: 8,790 units · 101 per 100k residents VA Maryland: 18,735 units · 303 per 100k residents MD Connecticut: 6,105 units · 169 per 100k residents CT Rhode Island: no data reported RI Arizona: 1,545 units · 20.8 per 100k residents AZ New Mexico: 2,070 units · 97.9 per 100k residents NM Kansas: 330 units · 11.2 per 100k residents KS Arkansas: no data reported AR Tennessee: 3,195 units · 44.8 per 100k residents TN North Carolina: 7,335 units · 67.7 per 100k residents NC South Carolina: 2,430 units · 45.2 per 100k residents SC Delaware: 1,275 units · 124 per 100k residents DE Oklahoma: 330 units · 8.1 per 100k residents OK Louisiana: 5,340 units · 117 per 100k residents LA Mississippi: 1,350 units · 45.9 per 100k residents MS Alabama: 2,175 units · 42.6 per 100k residents AL Georgia: 4,740 units · 43.0 per 100k residents GA D.C.: 2,130 units · 314 per 100k residents DC Hawaii: 1,455 units · 101 per 100k residents HI Texas: 6,255 units · 20.5 per 100k residents TX Florida: 7,050 units · 31.2 per 100k residents FL
Units reimbursed · per 100k residents
8.1655
gray = no data reported
Colors are per 100,000 residents, so big states don’t automatically dominate. Tap or hover a state for its actual totals.
Tap or hover a state
…for its Medicaid breakdown
🏆 Top states by units · per 100k residents
1 New Jersey 655 /100k
2 Michigan 381 /100k
3 New York 327 /100k
4 D.C. 314 /100k
5 Maryland 303 /100k
6 Pennsylvania 209 /100k
7 Washington 208 /100k
8 California 172 /100k
National units — by quarter
💵 About the dollar figures: “reimbursed” is what Medicaid paid pharmacies before confidential manufacturer rebates, so the program’s real net cost is lower than these numbers. Fee-for-service and managed-care claims are combined unless split above. Source: CMS State Drug Utilization Data; per-100k rates use 2023 Census population estimates.

💊 Medicaid utilization by pack size

Medicaid (SDUD) totals over the four most recent reported quarters for every package size of this drug — handy when a specific package (e.g. a starter/titration pack) carries little or no Medicaid volume on its own.
1 tube51672-1298-03 49,026 Rx · $1,117,896
1 tube51672-1298-02 44,157 Rx · $819,207
1 tube this page51672-1298-01 18,283 Rx · $245,171
Drug total (last 4 qtrs): 111,466 Rx · 5,054,151 units · $2,182,275 gross reimbursed
Tap a pack size to open its page. Source: CMS State Drug Utilization Data, last 4 quarters.

📊 Medicare Part D spend CMS · PART D · 2026 (Q1)

Medicare Part D (outpatient prescription) spending for Ketoconazole — the program that covers self-administered drugs. 13 manufacturers.
⚠️ Drug-level data: CMS publishes Part D spending by drug, not by NDC — these figures combine every manufacturer, strength and package size sold under the name Ketoconazole. That’s a different level of aggregation than the Medicaid card above, which is specific to this exact 11-digit NDC (pack size included), so the two aren’t directly comparable.
Period
Total Part D spend
$20.47M
Claims incl. refills
1.2M
Beneficiaries
831.7K
Spend / beneficiary
$24.61
Spend / claim
$17.69
Trend by period
💵 About the dollar figures: spending is what Part D plans paid before confidential manufacturer rebates, so the program’s real net cost is lower. A blank patient count means fewer than 11 people — CMS hides counts that small to protect privacy. Source: CMS Medicare Quarterly Part D Spending by Drug (data.cms.gov), updated quarterly.

🔬 Reported adverse events (FAERS)

Read carefully: FAERS reports are voluntary and unverified. Counts are not incidence, do not establish causation, are subject to reporting bias, and cannot be used to compare one drug to another. Shown for signal context only. Reports for Ketoconazole — the ingredient across all brands.

Top reported reactions

Pruritus984
Fatigue975
Nausea873
Rash858
Diarrhoea814
Headache754
Pain752

Reporter sex

0 reports

Serious outcomes

Death1,119
Life-threatening367
Disabling365
Reports over time (by year) — tap or hover for the count & year
2019 2021 2023 2026 1,596 0
Most recent year is provisional (FAERS lags ~3 months).
Where does this data come from?
Adverse-event reports from the FDA Adverse Event Reporting System (FAERS) via openFDA. FAERS reports are voluntary and unverified — counts are not incidence and don’t establish causation.

📦 Packaging — all sizes for this product

Package NDCDescription Per unit Per pack Marketing startStatus
51672-1298-01 You're viewing this 1 TUBE in 1 CARTON (51672-1298-1) / 15 g in 1 TUBE $0.3029 / g $4.54 2002-12-18 Active
51672-1298-02 1 TUBE in 1 CARTON (51672-1298-2) / 30 g in 1 TUBE $0.2544 / g $7.63 2002-12-18 Active
51672-1298-03 1 TUBE in 1 CARTON (51672-1298-3) / 60 g in 1 TUBE $0.1629 / g $9.77 2002-12-18 Active

Per g, this pack runs about 86% above the cheapest pack (NDC 51672-1298-03, $0.1629 vs $0.3029 NADAC).

This pack accounts for about 16% of this product's recent Medicaid fills; the largest share goes to a different pack size. See all packs ↓

Pack size FAQ

What quantity is in NDC 51672-1298-01?
NDC 51672-1298-01 is listed by the FDA — 1 tube in 1 carton / 15 g in 1 tube.
What NDC number is used to bill for this package of Ketoconazole 20 mg/g Cream?
Bill NDC 51672-1298-01 — the 11-digit billing format is 51672129801. Pharmacy and medical claims use the 11-digit form; the FDA label may print a shorter form of the same code.

Prices are the latest CMS NADAC pharmacy acquisition cost per NDC; per-pack figures are per-unit × pack quantity, shown only when the pack is denominated in the same measure NADAC prices.

📄 Full prescribing information FDA SPL

The complete FDA label for this product — the official prescribing information, verbatim, section by section. Jump with a chip, search within the label, or expand everything.
🎯 Indications and Usage 59 words

INDICATIONS AND USAGE Ketoconazole cream, 2% is indicated for the topical treatment of tinea corporis, tinea cruris and tinea pedis caused by Trichophyton rubrum, T. mentagrophytes and Epidermophyton floccosum; in the treatment of tinea (pityriasis) versicolor caused by Malassezia furfur (Pityrosporum orbiculare); in the treatment of cutaneous candidiasis caused by Candida spp. and in the treatment of seborrheic dermatitis.

⏱️ Dosage and Administration 123 words

DOSAGE AND ADMINISTRATION Cutaneous candidiasis, tinea corporis, tinea cruris, tinea pedis, and tinea (pityriasis) versicolor It is recommended that ketoconazole cream, 2% be applied once daily to cover the affected and immediate surrounding area. Clinical improvement may be seen fairly soon after treatment is begun; however, candidal infections and tinea cruris and corporis should be treated for two weeks in order to reduce the possibility of recurrence. Patients with tinea versicolor usually require two weeks of treatment.

Patients with tinea pedis require six weeks of treatment. Seborrheic dermatitis Ketoconazole cream, 2% should be applied to the affected area twice daily for four weeks or until clinical clearing. If a patient shows no clinical improvement after the treatment period, the diagnosis should be redetermined.

Contraindications 21 words

CONTRAINDICATIONS Ketoconazole cream, 2% is contraindicated in persons who have shown hypersensitivity to the active or excipient ingredients of this formulation.

⚠️ Warnings 9 words

WARNINGS Ketoconazole cream, 2% is not for ophthalmic use.

🤒 Adverse Reactions 71 words

ADVERSE REACTIONS During clinical trials 45 (5.0%) of 905 patients treated with ketoconazole cream, 2% and 5 (2.4%) of 208 patients treated with placebo reported side effects consisting mainly of severe irritation, pruritus and stinging. One of the patients treated with ketoconazole cream developed a painful allergic reaction. In worldwide postmarketing experience, rare reports of contact dermatitis have been associated with ketoconazole cream or one of its excipients, namely propylene glycol.

🤰 Pregnancy 82 words

Pregnancy Teratogenic effects Pregnancy Category C Ketoconazole has been shown to be teratogenic (syndactylia and oligodactylia) in the rat when given orally in the diet at 80 mg/kg/day, (10 times the maximum recommended human oral dose). However, these effects may be related to maternal toxicity, which was seen at this and higher dose levels. There are no adequate and well-controlled studies in pregnant women.

Ketoconazole should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

🧒 Pediatric Use 11 words

Pediatric Use Safety and effectiveness in children have not been established.

🧬 Clinical Pharmacology ~1 min read

CLINICAL PHARMACOLOGY When ketoconazole cream, 2% was applied dermally to intact or abraded skin of beagle dogs for 28 consecutive days at a dose of 80 mg, there were no detectable plasma levels using an assay method having a lower detection limit of 2 ng/mL. After a single topical application to the chest, back and arms of normal volunteers, systemic absorption of ketoconazole was not detected at the 5 ng/mL level in blood over a 72-hour period. Two dermal irritancy studies, a human sensitization test, a phototoxicity study and a photoallergy study conducted in 38 male and 62 female volunteers showed no contact sensitization of the delayed hypersensitivity type, no irritation, no phototoxicity and no photoallergenic potential due to ketoconazole cream, 2%.

Microbiology Ketoconazole is a broad spectrum synthetic antifungal agent which inhibits the in vitro growth of the following common dermatophytes and yeasts by altering the permeability of the cell membrane: dermatophytes: Trichophyton rubrum, T. mentagrophytes, T. tonsurans, Microsporum canis, M. audouini, M. gypseum and Epidermophyton floccosum; yeasts: Candida albicans, Malassezia ovale (Pityrosporum ovale) and C. tropicalis; and the organism responsible for tinea versicolor, Malassezia furfur (Pityrosporum orbiculare).

Only those organisms listed in the INDICATIONS AND USAGE section have been proven to be clinically affected. Development of resistance to ketoconazole has not been reported. Mode of Action In vitro studies suggest that ketoconazole impairs the synthesis of ergosterol, which is a vital component of fungal cell membranes.

It is postulated that the therapeutic effect of ketoconazole in seborrheic dermatitis is due to the reduction of M. ovale, but this has not been proven.

🧬 Mechanism of Action 49 words

Mode of Action In vitro studies suggest that ketoconazole impairs the synthesis of ergosterol, which is a vital component of fungal cell membranes. It is postulated that the therapeutic effect of ketoconazole in seborrheic dermatitis is due to the reduction of M. ovale, but this has not been proven.

📦 How Supplied / Storage and Handling 31 words

HOW SUPPLIED Ketoconazole cream, 2% is supplied in 15 g (NDC 51672-1298-1), 30 g (NDC 51672-1298-2), and 60 g (NDC 51672-1298-3) tubes. Store at 20°-25°C (68°-77°F) [see USP Controlled Room Temperature].

📦 Storage and Handling 9 words

Store at 20°-25°C (68°-77°F) [see USP Controlled Room Temperature].

📋 Description 70 words

DESCRIPTION Ketoconazole cream, 2% contains the broad-spectrum synthetic antifungal agent, ketoconazole 2%, formulated in an aqueous cream vehicle consisting of butylated hydroxyanisole (BHA), cetyl alcohol, isopropyl myristate, polysorbate 60, polysorbate 80, propylene glycol, purified water, sorbitan monostearate and stearyl alcohol. Ketoconazole is cis -1-acetyl-4-[4-[[2-(2,4-dichlorophenyl)-2-(1 H -imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl] piperazine and has the following structural formula: Molecular Formula: C 26 H 28 Cl 2 N 4 O 4 Molecular Weight: 531.43 Chemical Structure

Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA. Prefer the government’s original formatting? View this label on DailyMed ↗
For educational and professional reference only — not medical advice. Pricing reflects published NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.